Shanghai MicroPort MedBot Group Co

Shanghai MicroPort MedBot Group Co FCF per Share

The Free Cash Flow per Share of Shanghai MicroPort MedBot Group Co (2252.HK) as of Nov 1, 2026 is -0.04 CNY. In the previous year, Free Cash Flow per Share was -0.30 CNY — a change of -87.31% (higher).

FCF per Share

-0.04CNY

YoY

-87.31%

Last updated:

Free Cash Flow per Share of Shanghai MicroPort MedBot Group Co is 2025 -0.04 CNY. Free Cash Flow per Share of Shanghai MicroPort MedBot Group Co was 2024 -0.30 CNY. It decreases by -87.31% higher compared to the previous year.

The Shanghai MicroPort MedBot Group Co FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2019
-0.05 CNY
Jan 1, 2020
-0.15 CNY
Jan 1, 2021
-0.72 CNY
Jan 1, 2022
-1.14 CNY
Jan 1, 2023
-0.66 CNY
Jan 1, 2024
-0.30 CNY
Jan 1, 2025
-0.04 CNY
The Shanghai MicroPort MedBot Group Co FCF per Share history
YEARFCF per ShareYoY
-0.04CNY-87.31%
-0.30CNY-55.15%
-0.66CNY-41.98%
-1.14CNY+57.32%
-0.72CNY+395.05%
-0.15CNY+188.47%
-0.05CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shanghai MicroPort MedBot Group Co Stock analysis

What does Shanghai MicroPort MedBot Group Co do? Shanghai MicroPort MedBot Group Co Ltd designs, develops, and commercializes surgical robots for complex procedures, including the Toumai Laparoscopic Surgical Robot, DFVision 3D Electronic Laparoscope, and Honghu Orthopedic Surgical Robot. The company's products serve minimally invasive surgery fields such as endoscopic surgery, orthopedic surgery, pan-vascular surgery, natural cavity surgery, and percutaneous puncture surgery. They also provide education and training services for their MedBot surgical robot. The firm's primary customers are hospitals and surgical centers seeking advanced robotic-assisted surgical solutions. The company generates revenue through the sale of its surgical robots and related products, with the Toumai Laparoscopic Surgical Robot and Honghu Orthopedic Surgical Robot being key commercial products. The DFVision 3D Electronic Laparoscope is another product line contributing to sales. The firm targets healthcare institutions requiring minimally invasive surgical capabilities, focusing on orthopedic and endoscopic procedures where their robots offer precision and efficiency. Shanghai MicroPort MedBot Group's business model centers on selling surgical robots and training services to hospitals and surgical centers. The company's products are specifically designed for minimally invasive procedures across multiple surgical specialties. Revenue streams include direct product sales and educational services, with the Honghu Orthopedic Surgical Robot and Toumai Laparoscopic Surgical Robot being the main revenue drivers in the orthopedic and endoscopic surgery segments. Shanghai MicroPort MedBot Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai MicroPort MedBot Group Co stock

Free Cash Flow per Share of Shanghai MicroPort MedBot Group Co is -0.04 CNY in 2025.

Free Cash Flow per Share of Shanghai MicroPort MedBot Group Co changed from -0.30 CNY to -0.04 CNY, representing a -87.31% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Shanghai MicroPort MedBot Group Co since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Shanghai MicroPort MedBot Group Co

All Key Metrics — Shanghai MicroPort MedBot Group Co